MX355126B - Compuestos neuroesteroides. - Google Patents
Compuestos neuroesteroides.Info
- Publication number
- MX355126B MX355126B MX2015008264A MX2015008264A MX355126B MX 355126 B MX355126 B MX 355126B MX 2015008264 A MX2015008264 A MX 2015008264A MX 2015008264 A MX2015008264 A MX 2015008264A MX 355126 B MX355126 B MX 355126B
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- formula
- compounds
- apoptosis
- present
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 abstract 2
- 208000030507 AIDS Diseases 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 201000006474 Brain Ischemia Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000000474 Poliomyelitis Diseases 0.000 abstract 1
- 201000007737 Retinal degeneration Diseases 0.000 abstract 1
- 206010038848 Retinal detachment Diseases 0.000 abstract 1
- 208000006011 Stroke Diseases 0.000 abstract 1
- 208000030886 Traumatic Brain injury Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 230000005856 abnormality Effects 0.000 abstract 1
- 230000002424 anti-apoptotic effect Effects 0.000 abstract 1
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 208000014674 injury Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 210000000653 nervous system Anatomy 0.000 abstract 1
- 230000001537 neural effect Effects 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000001272 neurogenic effect Effects 0.000 abstract 1
- 230000009223 neuronal apoptosis Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000004258 retinal degeneration Effects 0.000 abstract 1
- 230000004264 retinal detachment Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
La presente invención se refiere a derivados de neuroesteroides novedosos con propiedades anti-apoptóticas, neuroprotectoras y neurogénicas que actúan en el sistema nervioso así como también a métodos para hacer los mismos y sus aplicaciones en el tratamiento y/o prevención o mejoramiento de enfermedades neurodegenerativas relacionadas con la apoptosis neuronal o lesión neuronal o condiciones relacionadas con o resultantes de la apoptosis, que incluyen pero no están limitadas a la enfermedad de Alzheimer, enfermedad de Parkinson, enfermedad de Huntington, esclerosis múltiple y esclerosis lateral amiotrófica (ALS), degeneración y desprendimiento de retina, neuoropatía periférica causada por anormalidades genéticas, diabetes, poliomielitis, herpes, SIDA y quimioterapia, traumatismo cerebral o isquemia y apoplejía. Los compuestos activos se representan por la Fórmula (I): en donde R1, R2, R3, R4, R5, R6, R7, A, B, X, Y y Z son como se define en la descripción de la invención. La presente invención también incluye composiciones las cuales comprenden uno o más de los compuestos de la fórmula (I).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0711948.0A GB0711948D0 (en) | 2007-06-20 | 2007-06-20 | Neurosteriod compounds |
| PCT/GB2008/002067 WO2008155534A2 (en) | 2007-06-20 | 2008-06-17 | Neurosteroid compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX355126B true MX355126B (es) | 2018-04-06 |
Family
ID=38352591
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015008264A MX355126B (es) | 2007-06-20 | 2008-06-17 | Compuestos neuroesteroides. |
| MX2009013189A MX2009013189A (es) | 2007-06-20 | 2008-06-17 | Compuestos neuroesteroides. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009013189A MX2009013189A (es) | 2007-06-20 | 2008-06-17 | Compuestos neuroesteroides. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9777037B2 (es) |
| EP (1) | EP2158209B1 (es) |
| JP (1) | JP5698974B2 (es) |
| KR (1) | KR101579323B1 (es) |
| CN (1) | CN101784558B (es) |
| AU (1) | AU2008265046C1 (es) |
| BR (1) | BRPI0813735A2 (es) |
| CA (1) | CA2691071C (es) |
| EA (1) | EA018632B1 (es) |
| GB (1) | GB0711948D0 (es) |
| IL (1) | IL202223B (es) |
| MX (2) | MX355126B (es) |
| WO (1) | WO2008155534A2 (es) |
| ZA (1) | ZA200908215B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2475369A1 (en) | 2009-09-11 | 2012-07-18 | Bionature E.A. Ltd. | Use of steroid compounds for inflammatory and autoimmune disorders |
| CN101884638B (zh) | 2010-07-09 | 2011-11-09 | 中山大学 | 5α-雄甾(烷)-3β,5,6β-三醇在制备神经元保护药物中的应用 |
| US9388210B2 (en) * | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| WO2013043985A1 (en) * | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| CN104136452A (zh) | 2011-10-14 | 2014-11-05 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| DK2806877T3 (da) | 2012-01-23 | 2019-11-04 | Sage Therapeutics Inc | Neuroaktive steroidformuleringer omfattende et kompleks af allopregnanolon og sulfobutylether beta-cyclodekstrin |
| US20140050789A1 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| CA2882708A1 (en) | 2012-08-21 | 2014-02-27 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| JP2016501876A (ja) | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
| RS57390B1 (sr) | 2012-12-18 | 2018-09-28 | Univ Washington | Neuroaktivni 19-alkoksi-17-supstituisani steroidi, primenjivi u postupcima lečenja |
| US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US9365502B2 (en) | 2013-03-11 | 2016-06-14 | Washington University | Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| EP2986623B1 (en) | 2013-04-17 | 2018-11-07 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-n-pyrazolyl steroids and methods of use thereof |
| SI2986624T1 (sl) | 2013-04-17 | 2020-10-30 | Sage Therapeutics, Inc. | 19-nor nevroaktivni steroidi za metode zdravljenja |
| CN103275070A (zh) * | 2013-05-10 | 2013-09-04 | 郑彪 | 调节单核细胞增殖的四环化合物及其应用 |
| SI3021852T1 (sl) | 2013-07-19 | 2021-07-30 | Sage Therapeutics, Inc. | Nevroaktivni steroidi, sestavki in uporabe le-teh |
| JP6466942B2 (ja) | 2013-08-23 | 2019-02-06 | セージ セラピューティクス， インコーポレイテッド | 向神経活性ステロイド、組成物、及びその使用 |
| ME03351B (me) * | 2014-01-29 | 2019-10-20 | Umecrine Cognition Ab | Steroidno jedinjenje za upotrebu u lečenju hepatične encefalopatije |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| RS60642B1 (sr) | 2014-10-16 | 2020-09-30 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| EP4527461A3 (en) | 2014-10-16 | 2025-06-25 | Sage Therapeutics, Inc. | A compound, compositions thereof and this compound for use in methods of treating cns disorders |
| SMT202000276T1 (it) | 2014-11-27 | 2020-07-08 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| AR103384A1 (es) | 2015-01-12 | 2017-05-03 | Umecrine Cognition Ab | 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA |
| SMT202100113T1 (it) | 2015-01-26 | 2021-05-07 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| WO2017156103A1 (en) | 2016-03-08 | 2017-09-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| NZ790187A (en) | 2016-07-11 | 2025-08-29 | Sage Therapeutics Inc | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| IL264129B2 (en) | 2016-07-11 | 2024-05-01 | Sage Therapeutics Inc | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| CN116059215B (zh) * | 2019-01-08 | 2025-10-03 | 成都康弘药业集团股份有限公司 | 甾体类化合物、用途及其制备方法 |
| JP2022532710A (ja) | 2019-05-10 | 2022-07-19 | ブリー バイオサイエンシーズ， インコーポレイテッド | ブレキサノロン、ガナキソロン、またはズラノロンを含有する薬学的組成物、及びそれらの使用 |
| SG11202112391UA (en) | 2019-05-31 | 2021-12-30 | Sage Therapeutics Inc | Neuroactive steroids and compositions thereof |
| RU2750639C1 (ru) * | 2021-04-27 | 2021-06-30 | ФЕДЕРАЛЬНОЕ ГОСУДАРСТВЕННОЕ БЮДЖЕТНОЕ УЧРЕЖДЕНИЕ НАУКИ ИНСТИТУТ ОРГАНИЧЕСКОЙ ХИМИИ им. Н.Д. ЗЕЛИНСКОГО РОССИЙСКОЙ АКАДЕМИИ НАУК (ИОХ РАН) | Замещенные спироандростен-17, 6'[1,3,4]тиадиазины, обладающие противовирусной активностью |
| CN115068681B (zh) * | 2022-06-10 | 2023-06-13 | 中国人民解放军空军特色医学中心 | 一种具有骨细胞脱落功能的PNIPAAm-g-PDA修饰PCL骨支架及其制备方法 |
| CN117003806A (zh) * | 2023-07-18 | 2023-11-07 | 湖北大学 | 具有抗帕金森病活性的甾体化合物及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3094521A (en) * | 1961-07-25 | 1963-06-18 | Merck & Co Inc | Alkanoylthio and pyrazolo androstane derivatives |
| US3364207A (en) | 1962-08-13 | 1968-01-16 | Searle & Co | Polyhydrospiro[estr/androst-4-ene-17, 2'-furan/pyran]-3-one and intermediates |
| US3300489A (en) | 1964-07-24 | 1967-01-24 | Smith Kline French Lab | Steroidal c-17 spirolactones and processes and intermediates used in the preparation thereof |
| US3320242A (en) | 1964-11-12 | 1967-05-16 | Parke Davis & Co | 17beta, 20-epoxy steroids and methods for their production |
| GB1089788A (en) | 1965-07-07 | 1967-11-08 | Parke Davis & Co | Process for the production of steroidal lactone compounds and intermediates thereof |
| US3413288A (en) | 1965-07-07 | 1968-11-26 | Parke Davis & Co | Process for the production of steroidal c-17 spirolactones |
| US3364238A (en) * | 1966-04-04 | 1968-01-16 | Searle & Co | 3-oxygenated spiro[androstene-17, 1'-cycloprop-2'-ene], 2', 3'-dihydro derivatives corresponding and intermediates thereto |
| US3365475A (en) | 1966-07-22 | 1968-01-23 | Merck & Co Inc | Process for the preparation of 17alpha-(3'-hydroxy-propyl)-4-androstene-3beta, 17beta-diol |
| DE2237143A1 (de) * | 1972-07-28 | 1974-02-14 | Hoechst Ag | Verfahren zur herstellung von beta(3-keto-7alpha-acetylthio-17beta-hydroxy4-androsten-17alpha-yl)-propionsaeuregamma-lacton und dessen 1-dehydro-derivat |
| DE2349023A1 (de) | 1973-09-26 | 1975-04-10 | Schering Ag | Neue d-homo-steroide |
| US3939155A (en) * | 1974-06-28 | 1976-02-17 | G. D. Searle & Co. | 4',5'-Dihydrospiro[androst/estr-4-ene-17,2'(3'H)-furan]3,4'-dione and congeners, and intermediates thereto |
| US4054563A (en) * | 1975-04-25 | 1977-10-18 | Ciba-Geigy Corporation | Process for the manufacture of spiro compounds of the steroid series |
| FR2596395B1 (fr) * | 1986-03-26 | 1989-05-26 | Roussel Uclaf | Nouveaux steroides comportant un cycle spirannique en position 17, leur procede de preparation, leur application comme medicaments et les compositions les renfermant |
| US5556847A (en) * | 1994-10-27 | 1996-09-17 | Duquesne University Of The Holy Ghost | Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors |
| WO1998005337A1 (en) * | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US5994334A (en) * | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| EP1310258A1 (en) | 2001-11-08 | 2003-05-14 | Etienne-Emile Baulieu | Enantiomers of steroids for the enhancement of memory and cognitive function |
| WO2007103162A2 (en) | 2006-03-01 | 2007-09-13 | Samaritan Pharmaceuticals, Inc. | Structure based drug design of steroidogenesis inhibitors |
-
2007
- 2007-06-20 GB GBGB0711948.0A patent/GB0711948D0/en not_active Ceased
-
2008
- 2008-06-17 EP EP08762391.4A patent/EP2158209B1/en active Active
- 2008-06-17 CN CN200880021099.6A patent/CN101784558B/zh active Active
- 2008-06-17 EA EA201070027A patent/EA018632B1/ru unknown
- 2008-06-17 WO PCT/GB2008/002067 patent/WO2008155534A2/en not_active Ceased
- 2008-06-17 JP JP2010512762A patent/JP5698974B2/ja active Active
- 2008-06-17 US US12/665,569 patent/US9777037B2/en active Active
- 2008-06-17 MX MX2015008264A patent/MX355126B/es unknown
- 2008-06-17 KR KR1020107001242A patent/KR101579323B1/ko active Active
- 2008-06-17 BR BRPI0813735-8A2A patent/BRPI0813735A2/pt not_active Application Discontinuation
- 2008-06-17 AU AU2008265046A patent/AU2008265046C1/en active Active
- 2008-06-17 MX MX2009013189A patent/MX2009013189A/es active IP Right Grant
- 2008-06-17 CA CA2691071A patent/CA2691071C/en active Active
-
2009
- 2009-11-19 IL IL202223A patent/IL202223B/en active IP Right Grant
- 2009-11-20 ZA ZA2009/08215A patent/ZA200908215B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0813735A2 (pt) | 2014-12-30 |
| JP2010530404A (ja) | 2010-09-09 |
| KR20100040292A (ko) | 2010-04-19 |
| KR101579323B1 (ko) | 2015-12-21 |
| WO2008155534A9 (en) | 2009-12-03 |
| WO2008155534A3 (en) | 2009-04-09 |
| CA2691071C (en) | 2016-06-07 |
| GB0711948D0 (en) | 2007-08-01 |
| EP2158209A2 (en) | 2010-03-03 |
| AU2008265046C1 (en) | 2018-08-16 |
| CA2691071A1 (en) | 2008-12-24 |
| AU2008265046A1 (en) | 2008-12-24 |
| EP2158209B1 (en) | 2019-02-27 |
| MX2009013189A (es) | 2010-04-09 |
| AU2008265046B2 (en) | 2014-07-17 |
| CN101784558B (zh) | 2014-07-02 |
| ZA200908215B (en) | 2011-02-23 |
| IL202223B (en) | 2018-06-28 |
| EA018632B1 (ru) | 2013-09-30 |
| US9777037B2 (en) | 2017-10-03 |
| WO2008155534A2 (en) | 2008-12-24 |
| EA201070027A1 (ru) | 2010-06-30 |
| US20100234335A1 (en) | 2010-09-16 |
| CN101784558A (zh) | 2010-07-21 |
| JP5698974B2 (ja) | 2015-04-08 |
| IL202223A0 (en) | 2010-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX355126B (es) | Compuestos neuroesteroides. | |
| WO2018015573A3 (en) | Trem2 cleavage modulators and uses thereof | |
| PH12018502101A1 (en) | Heterocyclic compound | |
| MX2020007318A (es) | Compuesto heterociclico. | |
| TW200634016A (en) | Novel thieno-pyridine and thieno-pyrimidine derivatives and their use as positive allosteric modulators of mglur2-receptors | |
| CA2560580A1 (en) | Imidazole compounds for inhibition of a.beta.-peptide production and for modulation of the notch signaling pathway | |
| CO2019006785A2 (es) | Inhibidores biciclo[1.1.1]pentano de la cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades | |
| EA017914B8 (ru) | 1,4-ДВУЗАМЕЩЕННЫЕ 3-ЦИАНОПИРИДОНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЗИТИВНЫХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2 | |
| MX2010002537A (es) | 4-fenil-1h-piridin-2-onas 1,3-disubstituidas. | |
| EA200971050A1 (ru) | Способы лечения и предупреждения нейродегенеративных заболеваний и нарушений | |
| MA38079A1 (fr) | Composés de 2-phényl-5-hétérocyclyl-tétrahydro-2h-pyran-3-amine destinés à être utilisés dans le traitement du diabète et de ses troubles associés | |
| TW200745135A (en) | Therapeutic agents | |
| CL2019000534A1 (es) | Inhibidores de cinasa de cremallera de leucina dual (dlk) para el tratamiento de enfermedades. | |
| CA2534532A1 (en) | Compounds for the treatment of neurodegenerative disorders | |
| MXPA05012196A (es) | Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos. | |
| ZA201003519B (en) | Piperidinyl and piperazinyl modulators of y-secretase | |
| MX2014000113A (es) | Compuestos para tratar neuropatias perifericas y otros desordenes neurodegenerativos. | |
| TW200635589A (en) | Therapeutic agents | |
| PT1656458E (pt) | Gene humano de susceptibilidade ao autismo e suas utilizações | |
| WO2005095348A3 (en) | Pyrazole-amine compounds for the treatment of neurodegenerative disorders | |
| WO2006087634A3 (en) | Uses of human autism susceptibility gene encoding a kinase | |
| IL185868A0 (en) | Human autism susceptibility gene encoding a transmembrane protein and uses thereof | |
| WO2007034326A3 (en) | Imidazole compounds for the treatment of neurological disorders | |
| MX2010004318A (es) | Moduladores de la gamma-secretasa con enlaces de amina. | |
| WO2011015646A3 (en) | Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders |